Antitumor activity of 3-indolylmethanamines 31b and ps121912

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 6001-6007

  Guthrie, Margaret L ^b,c   Sidhu, Preetpal S ^b,c   Hill, Emily K ^a   Horan, Timothy C ^a   Nandhikonda, Premchendar ^b,c   Teske, Kelly A ^b,c   Yuan, Nina Y ^b,c   Sidorko, Marina ^b,c   Rodali, Revathi ^b,c   Cook, James M ^b,c   Han, Lanlan ^b,c   Silvaggi, Nicholas R ^b,c   Bikle, Daniel D ^d   Moore, Richard G ^a   Singh, Rakesh K ^a   Arnold, Leggy A ^b,c  

^a BROWN UNIVERSITY   (United States)

^b Department of Chemistry and Biochemistry ^*  (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

3 Indolylmethanamine; Leukemia; Ovarian cancer

Indexed keywords

3 INDOLYLMETHANAMINE 31B; ANTINEOPLASTIC AGENT; CASPASE 3; FATTY ACID SYNTHASE; GLUCOSE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PS 121912; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 4-CHLORO-N-((2-CHLOROPHENYL)(2-METHYL-1H-INDOL-3-YL)METHYL)ANILINE; AMINE; ANILINE DERIVATIVE; AROMATIC HYDROCARBON; INDOLE DERIVATIVE; PS121912;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; FEMALE; GLUCOSE METABOLISM; GLYCOLYSIS; IN VIVO STUDY; LEUKEMIA; LIPOGENESIS; METABOLIC INHIBITION; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE;

AMINES; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROCARBONS, AROMATIC; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946067038     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Erspamer V: Pharmacology of indole-alkylamines. Pharmacol Rev 6: 425-487, 1954.
2. Snyder HR and Curtis WS: A convenient synthesis of DLtryptophan. JACS 66: 350-351, 1943.
3. Gill NS, James KB, Linos F and Potts K: P-Acylethylation with ketonic mannich bases. The synthesis of some diketones, ketonic sulfides, nitroketones and pyridines. JACS 74: 4923-4928, 1952.
4. Leete E and Marion L: The hydrogenolysis of 3-hydroxymethylindole and other indole derivatives with lithium aluminium hydride. Can J Chem 31: 775-784, 1953.
5. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, Botfield H, Young R, Ruddle R, Samuel L, Battersby A, Raynaud F, Allen N, Wilson S, Latinkic B, Workman P, McDonald E, Blagg J, Aherne W and Dale T: A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res 70: 5963-5973, 2010.
6. Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK and Arnold LA: Discovery of the first irreversible small molecule inhibitors of the interaction between the Vitamin D receptor and coactivators. J Med Chem 55: 4640-4651, 2012.
7. Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD and Arnold LA: Development of novel Vitamin D receptor-coactivator inhibitors. ACS Med Chem Lett 5: 199-204, 2014.
8. Sidhu PS, Teske K, Feleke B, Yuan NY, Guthrie ML, Fernstrum GB, Vyas ND, Han LL, Preston J, Bogart JW, Silvaggi NR, Cook JM, Singh RK, Bikle DD and Arnold LA: Anticancer activity of VDR-coregulator inhibitor PS121912. Cancer Chemoth Pharm 74: 787-798, 2014.
9. Peiffer L, Poll-Wolbeck SJ, Flamme H, Gehrke I, Hallek M and Kreuzer KA: Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. J Cancer Res Clin Oncol 140: 1283-1293, 2014.
10. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976-3985, 1993.
11. Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, Gitelis S, O'Keefe RJ, Konttinen YT, Yin G and Li TF: Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun 431: 274-279, 2013.
12. Sidhu PS, Teske K, Feleke B, Yuan NY, Guthrie ML, Fernstrum GB, Vyas ND, Han L, Preston J, Bogart JW, Silvaggi NR, Cook JM, Singh RK, Bikle DD and Arnold LA: Anticancer activity of VDR-coregulator inhibitor PS121912. Cancer Chemother Pharmacol 74: 787-798, 2014.
13. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
14. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301, 2010.
15. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
16. Jarde T, Evans RJ, McQuillan KL, Parry L, Feng GJ, Alvares B, Clarke AR and Dale TC: In vivo and in vitro models for the therapeutic targeting of Wnt signaling using a Tet-ODeltaN89beta-catenin system. Oncogene 32: 883-893, 2013.